CervoMed在2026年Ad/Pd™科学会议上公布了最新研究数据,这些数据强化了Neflamapimod药物对不伴有阿尔茨海默病共病理的路易体痴呆患者的治疗效果。新发现突显该疗法在特定患者群体中的显著优势,为精准医疗提供重要依据。
CervoMed在2026年Ad/Pd™科学会议上公布了最新研究数据,这些数据强化了Neflamapimod药物对不伴有阿尔茨海默病共病理的路易体痴呆患者的治疗效果。新发现突显该疗法在特定患者群体中的显著优势,为精准医疗提供重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.